MedTrace Logo

Osteocel® Plus in Anterior Lumbar Interbody Fusion (ALIF)

NCT00948831 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2025-12-24

No results posted yet for this study

Summary

This study is being conducted to determine the percentage of patients with solid spinal fusions after being treated with Osteocel Plus in an ALIF procedure. Due to the unique processing conditions, Osteocel Plus retains a high concentration of stem cells in conjunction with the allograft bone matrix, so it is hypothesized that the fusion rate with Osteocel Plus will be comparable to published data for autograft. The Osteocel product family has already been used in approximately 15,000 cases worldwide.

Conditions

  • Degenerative Disc Disease, Lumbar

Interventions

BIOLOGICAL

Osteocel Plus

biologic

Sponsors & Collaborators

  • NuVasive

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00948831 on ClinicalTrials.gov